Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation (DHR)
Danaher Corporation (DHR) reported new equity awards to its Senior Vice President and General Counsel, Jonathan Leiken. On November 15, 2025, he received 10,172 restricted stock units (RSUs)$0 per share. One third of these RSUs vest on each of the first, second, and third anniversaries of the grant date. On the same date, he was also granted an employee stock option to purchase 26,767 shares of common stock at an exercise price of $221.21 per share, with one third of the options becoming exercisable on each of the first three anniversaries of November 15, 2025.
Danaher Corporation (DHR)11/15/2025, Milosevich disposed of 35 shares of Danaher common stock at a price of $221.21 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on equity awards. Following this small transaction, he directly beneficially owns 4,420 shares of Danaher common stock. No derivative securities transactions were reported.
Danaher Corporation (DHR) reported an insider equity transaction by its Executive Vice President, Julie A. Sawyer Montgomery. On 11/15/2025, she disposed of 265 shares of Danaher common stock at a price of $221.21 per share, reported under transaction code F. Following this transaction, she beneficially owns 16,653 shares of Danaher common stock directly.
Danaher (DHR)
Danaher (DHR) reported an insider transaction by its EVP & Chief Financial Officer, Matthew McGrew. On 11/11/2025, he exercised 16,172 employee stock options at an exercise price of $62.85 per share and sold 16,172 common shares at a weighted average price of $214.6198.
Following these transactions, McGrew beneficially owns 20,062 common shares directly and 10,221.856 shares indirectly via a 401(k). The sale price reflected multiple trades between $214.580 and $214.810.
Danaher (DHR) insider transaction: Senior Vice President and General Counsel Brian W. Ellis reported option exercises and same‑day sales on 11/12/2025. He exercised employee stock options at $58.59 and sold the resulting shares in open market transactions at weighted average prices disclosed in footnotes.
Ellis exercised 7,109 options at $58.59, then sold 7,109 shares at $219.2131. He also exercised 14,667 options at $58.59, then sold 14,667 shares at $219.2321. Following these transactions, he beneficially owned 14,553 shares directly.
Footnotes state the sale prices were weighted averages within disclosed ranges, and describe the vesting schedules of the original option grants.
Danaher (DHR) director and officer Mitchell P. Rales reported open‑market sales totaling 437,000 shares of common stock on November 12, 2025 at weighted average prices of $217.64, $218.27, $219.43 and $220.15.
Following these transactions, he beneficially owns 553,228 shares directly. Indirect holdings include 912,654 shares through the Mitchell P. Rales Family Trust, 667 by a 401(k) plan, 3,256 in a trust for a daughter (plus another 3,256 in a second trust), and 25,671,000 shares through single‑member LLCs.
Danaher (DHR) disclosed insider activity by its SVP, Human Resources. On 11/10/2025, the officer exercised employee stock options for 4,176 shares at $88.24 (transaction code M), then sold 4,176 shares at a weighted average price of $210.4436 and 998 shares at $210.3118 (transaction code S).
The weighted average sale price reflects multiple trades between $210.4101 and $210.570. After these transactions, the officer beneficially owned 2,625 shares directly.
Danaher (DHR): A stockholder filed a Form 144 notice to sell up to 437,000 shares of common stock, with an aggregate market value of $91,743,780. The filing lists Monness, Crespi, Hardt & Co., Inc. as broker, an approximate sale date of 11/12/2025, and the NYSE as the exchange.
The seller previously acquired 1,900,000 shares on 06/11/2021 via a distribution from Capital Yield Corporation tied to a closely held corporation liquidation. In the past three months, Mitchell P. Rales reported a sale of 600,000 shares on 10/31/2025 for gross proceeds of $129,635,820. Shares outstanding were 706,349,563.